Spyre Therapeutics registers Phase 2 SKYLIGHT trial of SPY072 in hidradenitis suppurativa

Spyre Therapeutics registered one new trial this week covering its investigational drug SPY072.

• Spyre Therapeutics listed the Phase 2 "SKYLIGHT Trial" (NCT07766005) testing SPY072 given with bimekizumab against placebo plus bimekizumab in adults with moderate to severe hidradenitis suppurativa. The study will assess whether SPY072 improves hidradenitis suppurativa in adults with moderate to severe disease receiving advanced standard of care treatment.¹ The trial is not yet recruiting, with an estimated enrollment of 150 participants assigned by chance to receive either SPY072 or placebo for 16 weeks.¹ The primary endpoint is the percentage of participants achieving HiSCR75, defined by the study as at least a 75% reduction from baseline in total abscess and inflammatory nodule count, with no increase in abscess count and no increase in draining tunnel count, measured at Week 16.¹